Filtered By:
Specialty: Science
Condition: Thrombosis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 14 results found since Jan 2013.
Flu jab may reduce severe effects of Covid, suggests study
Analysis of 75,000 coronavirus patients found fewer major health problems among people with flu jabCoronavirus – latest updatesSee all our coronavirus coveragePeople who are vaccinated against influenza may be partly protected against some of the severe effects of coronavirus, and be less likely to need emergency care, according to a major study.The analysis of nearly 75,000 Covid patients found significant reductions in stroke, deep vein thrombosis (DVT) and sepsis, and fewer admissions to emergency departments and intensive care units, among those who had been given the flu jab.Continue reading...
Source: Guardian Unlimited Science - July 12, 2021 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Vaccines and immunisation Health UK news Source Type: news
Protease-independent action of tissue plasminogen activator in brain plasticity and neurological recovery after ischemic stroke Neuroscience
In this study, we investigated the role of tPA on primary neurons in culture and on brain recovery and plasticity after ischemic...
Source: Proceedings of the National Academy of Sciences - April 29, 2019 Category: Science Authors: Hongjian Pu, Yejie Shi, Lili Zhang, Zhengyu Lu, Qing Ye, Rehana K. Leak, Fei Xu, Shubei Ma, Hongfeng Mu, Zhishuo Wei, Na Xu, Yuguo Xia, Xiaoming Hu, T. Kevin Hitchens, Michael V. L. Bennett, Jun Chen Tags: PNAS Plus Source Type: research
Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury Neuroscience
Recombinant tissue plasminogen activator (tPA) is a Food and Drug Administration-approved thrombolytic treatment for ischemic stroke. tPA is also naturally expressed in glial and neuronal cells of the brain, where it promotes axon outgrowth and synaptic plasticity. However, there are conflicting reports of harmful versus neuroprotective effects of tPA in...
Source: Proceedings of the National Academy of Sciences - September 25, 2018 Category: Science Authors: Yuguo Xia, Hongjian Pu, Rehana K. Leak, Yejie Shi, Hongfeng Mu, Xiaoming Hu, Zhengyu Lu, Lesley M. Foley, T. Kevin Hitchens, C. Edward Dixon, Michael V. L. Bennett, Jun Chen Tags: PNAS Plus Source Type: research
Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation.
CONCLUSIONS: Patients with NVAF receiving rivaroxaban after RFCA procedures appear to benefit from a metabolic perspective compared with warfarin, providing practical clinical reference for the choice of the anticoagulant. Rivaroxaban seems to be as safe and effective in preventing thromboembolic events as warfarin for these patients.
PMID: 29119732 [PubMed - in process]
Source: J Zhejiang Univ Sci ... - November 1, 2017 Category: Science Authors: Zhu J, Gao RJ, Liu Q, Jiang RH, Yu L, Sun YX, Zhang P, Lin JW, Ye Y, Zhang ZW, Chen SQ, Cheng H, Sheng X, Jiang CY Tags: J Zhejiang Univ Sci B Source Type: research
Closing left atrial appendage reduces stroke risk from AFib
For patients with atrial fibrillation (AFib), a common heart rhythm disorder, closing the area of the heart known as the left atrial appendage as an add-on procedure during cardiac surgery was associated with a 40 percent reduction in the risk of thromboembolism (a condition when a blood clot forms and blocks an artery, which can cause a stroke or other complications) according to an observational study.
Source: ScienceDaily Headlines - March 20, 2017 Category: Science Source Type: news
Nanomedicine in the fight against thrombotic diseases
Ischemic heart disease and stroke caused by thrombus formation are responsible for more than 17 million deaths per year worldwide. Now researchers announce new research that has been covering the use of nanocarriers and microbubbles in drug delivery for thrombotic disease.
Source: ScienceDaily Headlines - July 6, 2015 Category: Science Source Type: news
A Hidden Danger In The New Versions Of Birth Control Pills
Women who take a newer version of birth control pills have a doubled risk of developing potentially fatal blood clots, according to a new study published in the British medical journal BMJ.
Venous thromboembolism is a serious condition that encompasses both deep vein thrombosis -- when a person develops a blood clot in the legs -- and pulmonary embolism, in which the clot travels to the lungs and obstructs breathing. VTE is potentially fatal, and the study indicates that women who take combined oral contraceptives with newer progesterone formulations are two times more likely to develop it as opposed to women who take a ...
Source: Science - The Huffington Post - May 27, 2015 Category: Science Source Type: news
Development of the Trevo ProVue Retriever for intracranial clot removal in acute ischemic stroke
It is estimated that 15 million people worldwide have a stroke each year. Of the estimated 795,000 strokes that occur in the United States annually, the majority are ischemic strokes resulting from an obstruction within a vessel supplying blood to the brain. The treatment goal for these patients is to restore blood flow as quickly as possible. Increasingly, endovascular treatments that interact directly with the clot are being pursued as options. Receiving U.S. Food and Drug Administration clearance in 2012, the Trevo® Retriever is a stent‐like structure to be deployed at the site of an occlusion to allow the occluding ...
Source: Annals of the New York Academy of Sciences - November 14, 2014 Category: Science Authors: Heather C. Prince, Amelia J. Saliba, Jaime Wheeler, Scott Bruder Tags: Original Article Source Type: research
Removing disordered regions of shape-shifting protein explains how blood clots
Researchers used x-ray crystallography to publish the first image of prothrombin. The protein’s flexible structure is key to the development of blood-clotting. Blood-clotting has long ensured our survival, stopping blood loss after an injury. However, when triggered in the wrong circumstances, clotting can lead to debilitating or fatal conditions such as a heart attack, stroke or deep vein thrombosis.
Source: ScienceDaily Headlines - July 15, 2014 Category: Science Source Type: news
Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involving the e...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis‐mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the prevention and treatment of these conditions have been dominated by oral vitamin K antagonists (such as warfarin) and the injectable heparins. Thrombosis can lead to several conditions, including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and/or death. Prevention and treatment of thrombosis with an effective, convenient‐to‐use oral anticoagula...
Source: Annals of the New York Academy of Sciences - May 23, 2013 Category: Science Authors: Troy C. Sarich, Gary Peters, Scott D. Berkowitz, Frank Misselwitz, Christopher C. Nessel, Paul Burton, Nancy Cook‐Bruns, Anthonie W.A. Lensing, Lloyd Haskell, Elisabeth Perzborn, Dagmar Kubitza, Kenneth T. Moore, Sanjay Jalota, Juergen Weber, Guohua Pan Tags: Original Article Source Type: research
Gene breakthrough boosts hope of drug for blood diseases
Discovery could prevent lethal blood clots and help children with rare platelet function disorderNoah Edwards is four years old and suffers from a disorder that prevents his blood from clotting. He bleeds profusely when cut and his face and body are easily bruised.His condition, called platelet function disorder, is a constant worry for his mother, Ruby. However, thanks to Noah's involvement in a remarkable project, funded by the British Heart Foundation, his prospects of leading a normal life have received a major boost.Researchers at Birmingham University have uncovered the genetic roots of platelet function disorder, a ...
Source: Guardian Unlimited Science - January 13, 2013 Category: Science Authors: Robin McKie Tags: University of Birmingham Genetics Biology News Medical research Higher education UK news The Observer Science Source Type: news
VWF linkage and GWAS Genetics
The plasma glycoprotein von Willebrand factor (VWF) exhibits fivefold antigen level variation across the normal human population determined by both genetic and environmental factors. Low levels of VWF are associated with bleeding and elevated levels with increased risk for thrombosis, myocardial infarction, and stroke. To identify additional genetic determinants of...
Source: Proceedings of the National Academy of Sciences - January 8, 2013 Category: Science Authors: Desch, K. C., Ozel, A. B., Siemieniak, D., Kalish, Y., Shavit, J. A., Thornburg, C. D., Sharathkumar, A. A., McHugh, C. P., Laurie, C. C., Crenshaw, A., Mirel, D. B., Kim, Y., Cropp, C. D., Molloy, A. M., Kirke, P. N., Bailey-Wilson, J. E., Wilson, A. F., Tags: Biological Sciences Source Type: research
Should Hillary Clinton be back at work so soon after a blood clot?
A doctor on whether the US secretary of state should be taking it easy after her health scareHillary Clinton is back at work today with 12 meetings scheduled this week, just four weeks after a blood clot on the brain. What advice would I give her if she pitched up at my GP surgery in north London?Her problems apparently kicked off at the beginning of December with a nasty European tummy bug. She became so dehydrated that she fainted and banged her head. She was admitted to hospital on 30 December and diagnosed with a right transverse venous sinus thrombosis (a blood clot in the large vein that runs in the space between bra...
Source: Guardian Unlimited Science - January 7, 2013 Category: Science Authors: Ann Robinson Tags: The Guardian Blogposts World news Health & wellbeing Society Neuroscience Features Life and style Hillary Clinton Source Type: news
